Company / Current Liabilities
Actinium Pharmaceuticals, Inc. Current Liabilities History
FY2011-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Current Liabilities
$8.0M
FY2025
5-year range
$6.8M / $10.6M
FY2021-FY2025
Trend
-2.2%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Current Liabilities has declined for 3 consecutive years, from $11M in FY2022 to $8M in FY2025.
Based on SEC 10-K filings.
$8M in FY2025 with a 3-year CAGR of -9.2%.
Improved from $8M to $8M over the past 2 years.
Current Liabilities over time
Growth rates
- 3-Year CAGR
- -9.2%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- Actinium Pharmaceuticals, Inc.'s current liabilities has declined for 3 consecutive years.
- 3-year CAGR of -9.2%, indicating a declining trend.
- In FY2025, current liabilities decreased 2.2% year-over-year.
- Peak current liabilities was recorded in FY2022.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -8.23 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Current LiabilitiesValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $8.0M | -2.2% |
| FY2024 | $8.1M | -4.1% |
| FY2023 | $8.5M | -20.1% |
| FY2022 | $10.6M | +55.4% |
| FY2021 | $6.8M | +31.3% |
| FY2011 | $5.2M | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026